Stock Track | 3SBIO Soars 11.66% Intraday as CICC Maintains Outperform Rating with 61% Upside Target

Stock Track04-01

3SBIO's stock surged 11.66% during intraday trading on Wednesday, following the release of a positive research report from CICC.

CICC maintained its Outperform rating on 3SBIO with a target price of HK$36.5, implying a 61% upside potential from current levels. The investment bank highlighted the smooth progress of the company's 707 collaboration with Pfizer, which is rapidly advancing overseas clinical trials, including global Phase III trials for NSCLC and CRC. CICC also noted the company's robust R&D pipeline, covering both oncology and autoimmune indications.

While CICC adjusted its 2026 net profit forecast due to timing changes in financial statement recognition for out-licensing revenue, the firm remains optimistic about 707's potential to become a cornerstone next-generation I/O therapy. The report also mentioned recent product approvals and new drug applications that are expected to contribute to future revenue growth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1147015943?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 14:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147015943","market":"us","top_or_hot":-1,"title":"Stock Track | 3SBIO Soars 11.66% Intraday as CICC Maintains Outperform Rating with 61% Upside Target","media":"Stock Track","content":"<p>3SBIO's stock surged 11.66% during intraday trading on Wednesday, following the release of a positive research report from CICC.</p><p>CICC maintained its Outperform rating on 3SBIO with a target price of HK$36.5, implying a 61% upside potential from current levels. The investment bank highlighted the smooth progress of the company's 707 collaboration with Pfizer, which is rapidly advancing overseas clinical trials, including global Phase III trials for NSCLC and CRC. CICC also noted the company's robust R&D pipeline, covering both oncology and autoimmune indications.</p><p>While CICC adjusted its 2026 net profit forecast due to timing changes in financial statement recognition for out-licensing revenue, the firm remains optimistic about 707's potential to become a cornerstone next-generation I/O therapy. The report also mentioned recent product approvals and new drug applications that are expected to contribute to future revenue growth.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | 3SBIO Soars 11.66% Intraday as CICC Maintains Outperform Rating with 61% Upside Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | 3SBIO Soars 11.66% Intraday as CICC Maintains Outperform Rating with 61% Upside Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-01 14:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>3SBIO's stock surged 11.66% during intraday trading on Wednesday, following the release of a positive research report from CICC.</p><p>CICC maintained its Outperform rating on 3SBIO with a target price of HK$36.5, implying a 61% upside potential from current levels. The investment bank highlighted the smooth progress of the company's 707 collaboration with Pfizer, which is rapidly advancing overseas clinical trials, including global Phase III trials for NSCLC and CRC. CICC also noted the company's robust R&D pipeline, covering both oncology and autoimmune indications.</p><p>While CICC adjusted its 2026 net profit forecast due to timing changes in financial statement recognition for out-licensing revenue, the firm remains optimistic about 707's potential to become a cornerstone next-generation I/O therapy. The report also mentioned recent product approvals and new drug applications that are expected to contribute to future revenue growth.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01530","symbol_name":"三生制药","start_time":0,"source_url":"","article_id":"1147015943","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147015943","pubTimestamp":1775024973,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"3SBIO's stock surged 11.66% during intraday trading on Wednesday, following the release of a positive research report from CICC.CICC maintained its Outperform rating on 3SBIO with a target price of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01530":"三生制药"},"translate_title":"个股轨迹|三生制药盘中大涨11.66%中金维持跑赢大盘评级目标61%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01530":1},"content_text":"3SBIO's stock surged 11.66% during intraday trading on Wednesday, following the release of a positive research report from CICC.CICC maintained its Outperform rating on 3SBIO with a target price of HK$36.5, implying a 61% upside potential from current levels. The investment bank highlighted the smooth progress of the company's 707 collaboration with Pfizer, which is rapidly advancing overseas clinical trials, including global Phase III trials for NSCLC and CRC. CICC also noted the company's robust R&D pipeline, covering both oncology and autoimmune indications.While CICC adjusted its 2026 net profit forecast due to timing changes in financial statement recognition for out-licensing revenue, the firm remains optimistic about 707's potential to become a cornerstone next-generation I/O therapy. The report also mentioned recent product approvals and new drug applications that are expected to contribute to future revenue growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1147015943","isCrawlerRequest":true}